Rituximab in the treatment of high responding inhibitors in severe haemophilia A

  • Moschovi M
  • Aronis S
  • Trimis G
 et al. 
  • 10


    Mendeley users who have this article in their library.
  • 17


    Citations of this article.


The development of antibodies to factor VIII (FVIII) in severely affected haemophilia A patients is a serious complication associated with increased morbidity and mortality. Bypassing agents are used to treat acute bleeding episodes; however, elimination of the inhibitors can only be achieved with immune tolerance therapy (ITT) in 60-80% of cases. High responding (HR) inhibitors are more likely to respond to ITT if the titre is decreased to

Author-supplied keywords

  • Children
  • High responding inhibitors
  • Immune tolerance therapy
  • Quality of life
  • Rituximab(anti-CD20)
  • Severe haemophilia

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • M. Moschovi

  • S. Aronis

  • Georgios Trimis

  • H. Platokouki

  • K. Salavoura

  • F. Tzortzatou-Stathopoulou

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free